Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression

doi:10.12092/j.issn.1009-2501.2019.09.017

Abstract

Abstract:

5-hydroxytryptamine reuptake inhibitor (SSRIs) has become a first-line anti-depressant in clinic,among which escitalopram is widely used in the treatment of major depression,and has achieved good therapeutic effect.However,for patients with gestational depression,the safety of using escitalopram during pregnancy is still uncertain.The safety and effectiveness of escitalopram in patients with gestational depression was reviewed in this paper.

Key words: escitalopram, depression, gestational, pregnancy

CLC Number:

R749

WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.

References

［1］汪天宇, 李英辉, 李磊, 等. 艾司西酞普兰治疗中国抑郁症患者有效性和安全性的Meta分析［J］. 中国临床药理学与治疗学, 2015, 20(9): 1020-1025.
［2］Si T, Wang G, Yang F, et al. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population［J］. Metab Brain Dis, 2017, 32(3): 891-901.
［3］O'leary N, Jairaj C, Molloy EJ, et al.Antenatal depression and the impact on infant cognitive, language and motor development at six and twelve months postpartum［J］. Early Hum Dev, 2019, 134: 41-46.
［4］蒋海霞, 左洁, 卫小玉, 等. 产妇焦虑、抑郁情绪与分娩方式及不良分娩结局的关系［J］. 检验医学与临床, 2018, 15(5): 623-625,628.
［5］杨洋. 产前抑郁影响因素及其妊娠结局［J］. 中国计划生育学杂志, 2019, 27(4): 504-507.
［6］Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors［J］. Am J Obstet Gynecol, 1989, 160(5 Pt 1): 1107-1111.
［7］Anderssion L,Sundstrom-popomaa I,Wulff M,et al.Implications of antenatal depression and anxiety for obstetric outcome［J］.Obstet Gynecol,2004,104(3):467-476.
［8］李大魁.治疗指南:精神病分册［M］. 2版. 北京:化学工业出版社, 2018:266-279.
［9］刘毅, 卓琳, 朱蓓, 等. 妊娠期抑郁症与新生儿低出生体重关系的Meta分析［J］. 中国当代儿科杂志, 2017, 19(9): 994-998.
［10］Betts KS, Williams GM, Najman JM, et al.Maternal depressive, anxious, and stress symptoms during pregnancy predict internalizing problems in adolescence［J］. Depress Anxiety, 2014, 31(1): 9-18.
［11］Van Batenburg-eddes T, Brion MJ, Henrichs J, et al. Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study［J］.J Child Psychol Psychiatry, 2013, 54(5): 591-600.
［12］Otake Y, Nakajima S, Uno A, et al.Association between maternal antenatal depression and infant development: a hospital-based prospective cohort study［J］. Environ Health Prev Med, 2014, 19(1): 30-45.
［13］National Institute for Health and Care Excellence. An tenatal and postnatal mental health:clinical management and service guidance(CG192)［EB/OL］.(2014-12-17)［2018-03-13］.https://www.nice.org.uk/guidance/cg192/chapter/1-Recommendations.
［14］Fatima M, Srivastav S, Mondal AC. Prenatal stress and depression associated neuronal development in neonates［J］. Int J Dev Neurosci, 2017, 60: 1-7.
［15］Tsuchimine S, Ochi S, Tajiri M, et al. Effects of cytochrome P450 (CYP) 2C19 genotypes on steady-state plasma concentrations of escitalopram and its desmethyl metabolite in japanese patients with depression［J］. Ther Drug Monit, 2018, 40(3): 356-361.
［16］Bourke CH, Stowe ZN, Neigh GN, et al.Prenatal exposure to escitalopram and/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats［J］. Neurotoxicol Teratol, 2013, 39: 100-109.
［17］Ehrlich DE, Neigh GN, Bourke CH, et al.Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats［J］. Neuropharmacology, 2015, 97: 251-258.
［18］Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate［J］. Pharmacopsychiatry, 2009, 42(3): 95-100.
［19］Loughhead AM,Fisher AD,Newport DJ,et al.Antidepressants in amniotic fluid:another route of fetal exposure［J］.Am J Psychiatry,2006,163(1):145-147.
［20］Klieger-Grossmann C, Weitzner B, Panchaud A, et al.Pregnancy outcomes following use of escitalopram［J］. J Clin Pharmacol，2012,52(5): 766-770.
［21］Viktorin A, Uher R, Reichenberg A, et al. Autism risk following antidepressant medication during pregnancy［J］. Psychol Med, 2017, 47(16): 2787-2796.
［22］Reefhuis J, Devine O, Friedman JM, et al. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports［J］. BMJ, 2015, 351: h3190.
［23］Bellantuono C, Bozzi F, Orsolini L.Safety of escitalopram in pregnancy: a case series［J］. Neuropsychiatr Dis Treat, 2013, 9: 1333-1337.
［24］Orsolini L, Bozzi F, Bellantuono C.Psychopharmacological treatment in pregnancy and in breastfeeding: focus on escitalopram［J］. Eur Neuropsychopharmacol, 2013, (Suppl 2): S399-S400.
［25］Degiacomo J, Luedtke S. Neonatal toxicity from escitalopram use in utero: a case report［J］. J Pediatr Pharmacol Ther, 2016, 21(6): 522-526.
［26］Gentile S. Escitalopram late in pregnancy and while breast-feeding［J］. Ann Pharmacother, 2006, 40(9): 1696-1697.
［27］徐虹, 孙锟, 李智平, 等. 临床药物治疗学［M］. 北京:人民卫生出版社, 2016
［28］Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment［J］. Jama, 2006, 295(5): 499-507.
［29］高杉, 黄桦, 王晶晶, 等. 5-羟色胺再摄取抑制剂在妊娠期抑郁患者中使用的安全性研究［J］. 中国药房, 2018, 29(17): 2439-2443.
［30］喻东山. 抗抑郁药对妊娠和哺乳的影响［J］. 临床精神医学杂志, 2012, 22(1): 60-62.
［31］白梦如, 孙冬黎, 蒋惠娣, 等. 胎盘中转运体的功能性表达与调控［J］. 药学学报, 2016, 51(6): 879-885.
［32］Wang JS, Newport DJ, Stowe ZN, et al. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient［J］. Drug Metab Rev, 2007, 39(4): 723-746.
［33］Kliman HJ, Quaratella SB, Setaro AC, et al. Pathway of maternal serotonin to the human embryo and fetus［J］. Endocrinology, 2018, 159(4): 1609-1629.
［34］Joshi AA, Vaidya SS, St-pierre MV, et al. Placental ABC transporters: biological impact and pharmaceutical significance［J］. Pharm Res, 2016, 33(12): 2847-2878.
［35］Bundgaard C, Eneberg E, Sanchez C.P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo［J］. Neuropharmacology, 2016, 103: 104-111.
［36］Zhu HJ, Appel DI, Grundemann D, et al. Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action［J］. Pharmacol Res, 2012, 65(4): 491-496.
［37］Huang H, Wang J, Li Q, et al. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population［J］. J Matern Fetal Neonatal Med, 2017, 30(11): 1288-1292.

[1]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[2]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[3]	LIU Xin, LENG Yufang, ZHANG Xuehong, ZHANG Lili, ZHANG Mengjie, QU Shanshan, XIE Jianqin, WANG Yiqing. Application of nalbuphine in ultrasound-guided transvaginal oocyte retrieval and its effect on embryo quality and pregnancy outcome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1042-1047.
[4]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[5]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[6]	JIANG Weijie, HE Haibo, TANG Hongbo, HE Junyu. Research progress on the relationship between nuclear factor-κB in placenta and pregnancy complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 82-87.
[7]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[8]	HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
[9]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[10]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[11]	ZHOU Yancan. Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 699-703.
[12]	CHEN Lianzhou, LI Songhua, PU Ben. Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 446-450.
[13]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.
[14]	WANG Rouxin, FANG Zekang, YAO Siqi, XUE Yingying, ZHAO Yeying, YE Yilu. Effects of nicotinamide ribose on adolescent depression rats after neonatal maternal deprivation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1015-1021.
[15]	WU Mengyao, ZHAO Hongqing, WANG Yuhong. Advances of the ion channels related to depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 949-954.